129 Xenon - Polarean Imaging
Alternative Names: 129Xe-MRI; 129Xenon-MRI; Xenon Xe 129 hyperpolarized; XENOVIEWLatest Information Update: 13 Sep 2023
At a glance
- Originator GE Healthcare
- Developer Polarean Imaging
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Lung disorders
Most Recent Events
- 08 Sep 2023 Polarean Imaging partnered with VIDA Diagnostics to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
- 08 Sep 2023 Launched for Lung disorders (Diagnosis, In adolescents, In adults) in USA (Inhalation)
- 26 Dec 2022 129 Xenon is still in preregistration for Lung disorders in USA (Polarean Imaging pipeline, December 2022)